EPIX Pharmaceuticals Inc.

epix pharmaceuticals inc. - All News and Analysis

• EPIX Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript

  Seeking Alpha - 2008-09-23

  Earnings Call ExcerptEPIX Pharmaceuticals Inc. EPIX Q2 2008 Earnings Call August 7, 2008 10:00 am ET Executives Elkan Gamzu - Interim Chief Executive Officer Kimberlee Cobleigh Drapkin - Chief Financial Officer Analysts Mike Yee - RBC Capital Markets Alan Carr - Needham & Co Jon Lecroy -...

  Tags: EPIX Pharmaceuticals Inc.

• EPIX Pharmaceuticals Secures Committed Equity Financing Facility

  - 2008-08-05

  Financing Facility May Provide Up To $50 Million of Capital LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that it has entered into a...

  Tags: agreement, EPIX Pharmaceuticals Inc., equity, FINANCE, financing, Investment, SEC, warrant

• EPIX Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript

  Seeking Alpha - 2008-02-25

  Question-and-Answer Session Operator Thank you. Operator Instructions And your first question comes from the line of Ted Tenthoff with Piper Jaffray. Ted Tenthoff - Piper Jaffray Great. Thank you very much. Can you hear me at here Michael? Michael Kauffman We can. Ted Tenthoff - Piper Jaffray Great. How...

  Tags: EPIX Pharmaceuticals Inc.

Additional Resources

• EPIX Pharmaceuticals Announces FDA Approval of Vasovist®

  - 2008-12-22

  First Imaging Agent Approved for Magnetic Resonance Angiography MRA in the U.S. LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that the U.S....

• EPIX Pharmaceuticals Receives NASDAQ Compliance Notice; Intends to Request Hearing

  - 2008-11-11

  LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that, as expected, it received a notice from the Listing Qualifications Staff of The Nasdaq Stock...

• EPIX Pharmaceuticals Announces Third Quarter Financial Results

  - 2008-11-04

  Company Reduces Net Loss Expectation for 2008 Conference Call to be Held Today at 10:00 a.m. EST LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform...

• EPIX Pharmaceuticals Announces Third Quarter 2008 Financial Results Release Date and Conference Call

  - 2008-10-28

  Financial Results to be Released and Call to be Held Tuesday, November 4, 2008 LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that...

• EPIX Pharmaceuticals Announces Reduction in Force

  - 2008-10-23

  LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it is reducing its cost structure by decreasing its workforce by approximately 23% and narrowing...

• EPIX Pharmaceuticals to Present at the North American Cystic Fibrosis Conference

  - 2008-10-21

  LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that Martin Mense, Ph.D., principal scientist and head of Cystic Fibrosis biology at EPIX, is scheduled...

• EPIX Pharmaceuticals to Present at the Alzheimer's Association Research Roundtable Meeting

  - 2008-10-16

  LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that J. Thomas Megerian, M.D., Ph.D., executive director for clinical development at EPIX, is scheduled to...

• EPIX Pharmaceuticals Receives NASDAQ Compliance Notice

  - 2008-10-14

  LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that it received notice from The NASDAQ Stock Market dated October 10, 2008 that it is...

• EPIX Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference

  - 2008-10-06

  LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it is scheduled to present at the Natixis Bleichroeder Second Annual Hidden Gems Conference on...

• EPIX Pharmaceuticals to Present at the 2008 Maxim Group Growth Conference

  - 2008-09-30

  LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it is scheduled to present at the 2008 Maxim Group Growth Conference on Tuesday, October...

• EPIX Pharmaceuticals Achieves Milestone from Collaboration with Cystic Fibrosis Foundation Therapeutics

  - 2008-09-16

  Company to Receive $500,000 Milestone Payment LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it has achieved another milestone in its collaboration...

• EPIX Pharmaceuticals To Regain Full Worldwide Commercial Rights For Vasovist®

  - 2008-09-04

  Vasovist PDUFA Date of December 31, 2008 Unchanged; EPIX Continues to Focus On Monetization Strategy LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced...

• EPIX Pharmaceuticals Announces Formation of Technology Advisory Board

  - 2008-08-14

  Board Comprised of Leaders in the Computational Technologies Field LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced the formation of a Technology Advisory...

• EPIX Pharmaceuticals Initiates Phase 2b Right-Heart Catheterization Study of PRX-08066 in Patients with Chronic Obstructive Pulmonary Disease and Moderate-to-Severe Pulmonary Hypertension

  - 2008-08-12

  PRX-08066 may represent a novel mechanism for selectively dilating diseased pulmonary arteries without affecting systemic blood pressure LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform,...

• EPIX Pharmaceuticals Announces Second Quarter Financial Results

  - 2008-08-07

  Company Continues to Make Progress Across Clinical and Preclinical Development Programs Conference Call to be Held Today at 10:00 a.m. EST LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly...

• EPIX Pharmaceuticals Secures Committed Equity Financing Facility

  - 2008-08-05

  Financing Facility May Provide Up To $50 Million of Capital LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that it has entered into...

• EPIX Pharmaceuticals Announces Second Quarter 2008 Financial Results Release Date and Conference Call

  - 2008-07-31

  Financial Results to be Released and Call to be Held Thursday, August 7, 2008 LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that...

• Incorporated: 1988
• CEO: Dr. Elkan R. Gamzu Ph.D.
• Employees: 119